31 completed, 8 terminated, 6 withdrawn, 5 active not recruiting. 25 Phase 3, 9 Phase 2, 8 Not applicable, 8 Phase 1, 6 Phase 4.
Follow Lennox Gastaut Syndrome: new trials by email Literature Review of Lennox Gastaut Syndrome trials Research Report on Lennox Gastaut Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sleep-Driven Adaptive Neuromodulation in Lennox-Gastaut Syndrome Personalized Adaptive Deep Brain Stimulation Therapy, Conventional Non-Personalized Deep Brain Stimulation Therapy - Lennox Gastaut Syndrome (LGS), Epilepsy | Not applicable | Not yet recruiting | University of Minnesota | 4 | 2027-01-01 | 2026-10-07 |
| A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex Epidiolex 100 mg/mL Oral Solution - Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | Phase 4 | Not yet recruiting | Elizabeth Donner | 25 | 2027-01-01 | 2026-09-11 |
| A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS Cannabidiol Oral Solution - Lennox-Gastaut Syndrome | Phase 4 | Not yet recruiting | Jazz Pharmaceuticals | 40 | 2026-11-18 | 2026-10-22 |
| EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment fenfluramine HCl - Lennox Gastaut Syndrome (LGS) | Enrolling by invitation | University of Chicago | 20 | 2026-05-01 | 2026-08-06 | |
| Clinical Utility of Reduced EEG Home Monitoring in Fenfluramine Titration for Dravet and LGS Byteflies Remote patient monitoring solution (with reduced EEG) - Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS) | Not applicable | Enrolling by invitation | Byteflies | 20 | 2026-04-20 | 2026-10-08 |
| The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial Deep Brain Stimulation - Lennox Gastaut Syndrome (LGS) | Not applicable | Recruiting | University College, London | 22 | 2026-03-24 | 2026-04-07 |
| An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome Clemizole HCl, Placebo - Lennox Gastaut Syndrome | Phase 3 | Recruiting | Epygenix | 260 | 2025-04-09 | 2026-10-09 |
| Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY Epidiolex 100 mg/mL Oral Solution - Lennox Gastaut Syndrome, Dravet Syndrome | Active not recruiting | Jazz Pharmaceuticals | 111 | 2025-02-24 | 2026-06-03 | |
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) LP352 - Developmental and Epileptic Encephalopathy | Phase 3 | Enrolling by invitation | Longboard Pharmaceuticals | 324 | 2025-02-12 | 2026-10-14 |
| CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | Phase 1 / Phase 2 | Not yet recruiting | Alexander Rotenberg | 25 | 2025-01-01 | 2024-12-18 |
| BMB-101 in Absence Epilepsy and DEE BMB-101 - Absence Epilepsy, Jeavons Syndrome | Phase 2 | Recruiting | Bright Minds Biosciences Pty Ltd | 20 | 2024-12-05 | 2025-08-12 |
| A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in Portugal No Intervention - Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | Withdrawn | Takeda | 2024-12-01 | 2026-08-17 | ||
| A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) LP352, Placebo - Developmental and Epileptic Encephalopathy | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 367 | 2024-11-11 | 2026-09-15 |
| Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut Syndrome Forel's Field H-DBS ON - Lennox Gastaut Syndrome | Not applicable | Active not recruiting | Liankun_Ren | 5 | 2024-05-01 | 2026-04-13 |
| A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine Soticlestat - Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | Phase 3 | Terminated | Takeda | 1 | 2024-04-25 | 2026-09-04 |
| A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain No intervention - Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | Completed | Takeda | 237 | 2023-10-26 | 2026-08-18 | |
| Children's Adaptive Deep Brain Stimulation for Epilepsy Trial (CADET): Pilot Deep brain stimulation - Epilepsy, Lennox-Gastaut Syndrome, Intractable | Not applicable | Completed | University College, London | 4 | 2023-06-02 | 2025-08-28 |
| Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy LP352, bexicaserin - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 2 | Completed | Longboard Pharmaceuticals | 41 | 2022-11-08 | 2025-12-03 |
| RNS System LGS Feasibility Study RNS System - Epilepsy, Lennox Gastaut Syndrome | Phase 2 | Active not recruiting | NeuroPace | 24 | 2022-10-04 | 2026-09-15 |
| Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults Carisbamate - Seizures, Lennox Gastaut Syndrome | Phase 3 | Recruiting | SK Life Science, Inc. | 252 | 2022-04-28 | 2025-07-24 |
Showing 20 of 68. Sign in to see all of them.
Epilepsy (30) · Epilepsies, Myoclonic (26) · Seizures (22) · Tuberous Sclerosis (8) · Spasms, Infantile (5) · CDKL5 deficiency disorder (4) · Epilepsies, Partial (4) · Epilepsy, Generalized (3) · Brain Diseases (2) · Malformations of Cortical Development (2) · Neurodevelopmental Disorders (2) · Syncope (2) · Central Nervous System Diseases (1) · Drug Resistant Epilepsy (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (68) · Epileptic Syndromes (68) · Genetic Diseases, Inborn (68) · Central Nervous System Diseases (67) · Nervous System Diseases (67) · Brain Diseases (66) · Epilepsy (38) · Epilepsy, Generalized (27) · Pathological Conditions, Signs and Symptoms (24) · Signs and Symptoms (23) · Neurologic Manifestations (22) · Congenital Abnormalities (9) · Nervous System Malformations (9) · Hamartoma (8) · Heredodegenerative Disorders, Nervous System (8)
Cannabidiol (14) · rufinamide (5) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (4) · soticlestat (4) · Fenfluramine (3) · Topiramate (3) · Clobazam (2) · Deep Brain Stimulation (2) · Solutions (2) · perampanel (2) · Curcumin (1) · Diet, Ketogenic (1) · Fluorodeoxyglucose F18 (1) · Medical Marijuana (1) · Melatonin (1)
Jazz Pharmaceuticals (7) · Takeda (7) · Longboard Pharmaceuticals (5) · Eisai Inc. (4) · SK Life Science, Inc. (4) · Eisai Co., Ltd. (2) · Eisai Limited (2) · Gillette Children's Specialty Healthcare (2) · INSYS Therapeutics Inc (2) · Lundbeck LLC (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · University College, London (2) · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (2) · Alexander Rotenberg (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1)
United States (38) · Australia (16) · Spain (15) · Italy (12) · Poland (12) · Canada (11) · Belgium (9) · China (9) · France (9) · Japan (9) · Germany (8) · Netherlands (7) · Serbia (7) · United Kingdom (7) · Mexico (6)
Marc Kamin, MD (3) · Dennis J Dlugos, MD (2) · Hiroki Takano (2) · Neha Parikh (2) · Alexander Rotenberg, MD, PhD (1) · Alexis Arzimanoglou Arzimanoglou (1) · Amit Ray, MD (1) · Beverly S Wical, MD (1) · Daniel Lowenstein, MD (1) · Elizabeth Donner, MD (1)
PMID 33825230, PMID 27683846, PMID 29768152, PMID 33797076, PMID 37052803, PMID 40775196, PMID 10371538, PMID 21956725, PMID 23141144, PMID 26805435, PMID 27199889, PMID 28538134, PMID 28927712, PMID 30146701, PMID 30309816, PMID 30955420, PMID 31168494, PMID 31333569, PMID 32917807, PMID 33179247, PMID 34287833, PMID 34406656, PMID 35499850, PMID 35841234, PMID 40606139, PMID 42663529
2014 (4), 2018 (2), 2017 (1), 2019 (1), 2023 (1), UH3NS109557 (1)